Voyager spells out its $92M IPO pitch as Wall Street sours on biotech

Gene therapy developer Voyager Therapeutics is angling for as much as $92 million in a planned IPO, braving choppy waters for biotech after a string of disappointing debuts for life sciences companies. The company, a 2014 Fierce 15 honoree, is planning to offer about 4.7 million shares at between $15 and $17 each, setting aside another 703,125 shares for its underwriters to cover overalotments and trading under "VYGR" thereafter. Voyager's scheduled IPO comes amid an increasingly tough climate for biotech debutantes, as MyoKardia ($MYOK), Dimension Therapeutics ($DMTX), CytomX Therapeutics ($CTMX) and others have all priced at significant discounts over the past month. Voyager's lead program is a potential treatment for Parkinson's disease, and the company is working with Sanofi ($SNY) in a collaboration worth up to $845 million. More

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.